Innovative Therapies Centers of Excellence Act
- Bill Number
- S. 4031
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Armed Forces and National Security
- Status
- Introduced
- Latest Action
- 2026-03-09: Read twice and referred to the Committee on Veterans' Affairs.
- Last Updated
- 2026-04-01T20:32:21Z
AI-Generated Summary
Purpose
The Innovative Therapies Centers of Excellence Act aims to improve the Department of Veterans Affairs (VA) healthcare system by establishing specialized centers focused on researching, educating, and providing innovative therapies for certain mental health, chronic pain, and neurological conditions affecting veterans. These centers would prioritize cutting-edge treatments to enhance care delivery.
Key Provisions
- Designation and Establishment: The Secretary of Veterans Affairs, based on recommendations from the Under Secretary for Health, must designate at least five VA medical facilities as "innovative therapies centers of excellence." These centers would be established and operated subject to available funding.
- Geographic Distribution: Designations must ensure the centers are spread across different regions of the U.S. to promote nationwide access.
- Designation Requirements: Facilities can only be selected if they meet high standards, including:
- Approval from a peer review panel for scientific and clinical merit.
- Affiliations with accredited medical schools (for innovative therapies training), schools of psychiatry, and schools of social work.
- Ability to attract creative researchers.
- An advisory committee including veterans and medical experts to guide policy.
- Capabilities for evaluating center activities, coordinating national education/research/clinical efforts, forming provider consortia for broader access, and creating a national data repository on veteran treatments.
- Peer Review Panel: The Under Secretary for Health must create a panel of experts in innovative therapies to evaluate proposals. Members serve up to two years (with staggered initial terms), and the panel is exempt from standard federal advisory committee rules under the Federal Advisory Committee Act.
- Reporting: Starting two years after enactment, the Under Secretary must submit annual reports to Senate and House Veterans' Affairs Committees, covering center activities, key findings, recommendations for improving therapy delivery, and other relevant matters.
- Funding: Authorizes $30 million annually for research and education at the centers. Additional funds from VA's general medical services and research accounts can be allocated as needed.
- Definitions:
- Covered conditions: Includes anxiety, bipolar disorder, chronic pain, depression, Parkinson's disease, post-traumatic stress disorder (PTSD), substance use disorder, and others designated by the Under Secretary.
- Innovative therapy: Refers to substances like 3,4-Methylenedioxy-methamphetamine (MDMA), 5-Methoxy-N,N-dimethyltryptamine, ibogaine, ketamine, psilocybin (a psychedelic compound), and others designated by the Under Secretary.
Significant Changes to Existing Law
This bill amends title 38 of the U.S. Code (which governs veterans' benefits) by adding a new section (7330E) to subchapter II of chapter 73. This creates a formal framework for these centers, which did not previously exist in VA law. It introduces mandatory designations, peer review processes, and specific funding authorizations tailored to innovative therapies, building on but expanding existing VA research and affiliation authorities without altering broader healthcare structures.
Potential Impacts
- On Government Agencies: The VA would need to invest in facility upgrades, partnerships, and data systems, potentially straining resources if appropriations fall short. It could enhance the VA's role as a leader in medical innovation, with annual reporting increasing congressional oversight.
- On Citizens (Veterans): Veterans with covered conditions may gain better access to advanced, evidence-based treatments like psychedelic-assisted therapies, potentially improving mental health outcomes and reducing reliance on traditional medications. A national data repository could lead to more personalized care across VA facilities.
- On International Relations: No direct impacts; the bill focuses on domestic VA operations.
Main Stakeholders Affected
- Veterans: Primary beneficiaries, especially those with PTSD, depression, chronic pain, or substance use issues, who could receive specialized care.
- VA Facilities and Staff: Selected medical centers would host operations, requiring collaboration among doctors, researchers, and administrators.
- Educational Institutions: Accredited medical, psychiatry, and social work schools affiliated with VA facilities would provide training and research support.
- Researchers and Experts: Scientists and peer review panel members involved in evaluating and advancing innovative therapies.
- Congress: Receives ongoing reports, influencing future VA funding and policy.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill authorizes research and use of controlled substances (e.g., MDMA and psilocybin, classified as Schedule I drugs under federal law) within the VA system, which could require coordination with the Drug Enforcement Administration for exemptions or approvals. It also exempts the peer review panel from certain federal advisory rules, streamlining operations but potentially limiting public input.
- Constitutional: Aligns with Congress's authority under Article I to regulate veterans' affairs and appropriate funds; no apparent conflicts with due process or equal protection, as it targets VA-eligible individuals.
- Political: Introduced bipartisanship (by Sens. Gallego and McCormick), it signals growing support for psychedelic and alternative therapies in veteran care amid national mental health discussions, but implementation may face debates over drug policy and funding priorities.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2026-03-09: Read twice and referred to the Committee on Veterans' Affairs.
- 2026-03-09: Introduced in Senate
Bill Versions
- Innovative Therapies Centers of Excellence Act — issued 2026-03-09 — PDF (8 pages)